Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.42 |
| ▸ | JAK1 | P23458 | 14/20 | 0.42 |
| ▸ | JAK3 | P52333 | 14/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922865 | 1.00 | JAK2 (0.42) | JAK2JAK1JAK3EGLN2PIM1 | |
| SCHEMBL376523 | 0.88 | JAK1 (0.40) | JAK2JAK1JAK3PIM1PIM2 | |
| SCHEMBL376522 | 0.88 | JAK1 (0.40) | JAK2JAK1JAK3PIM1PIM2 | |
| SCHEMBL376579 | 0.88 | JAK2 (0.46) | JAK2JAK1JAK3EGLN2 | |
| SCHEMBL15167665 | 0.86 | JAK2 (0.54) | JAK2JAK1JAK3 | |
| SCHEMBL15167662 | 0.86 | JAK2 (0.54) | JAK2JAK1JAK3 | |
| SCHEMBL376478 | 0.85 | JAK2 (0.41) | JAK2JAK1JAK3PIM1PIM2 | |
| SCHEMBL376477 | 0.85 | JAK2 (0.41) | JAK2JAK1JAK3PIM1PIM2 | |
| SCHEMBL15167380 | 0.84 | JAK2 (0.42) | JAK2JAK1JAK3PIM1PIM2 | |
| SCHEMBL15167383 | 0.84 | JAK2 (0.42) | JAK2JAK1JAK3PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518952-B2 | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | JAK2 1001/4885JAK1 631/4885JAK3 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.